rituximab/cyclophosphamide/doxorubicin/vincristine (Oncocin)/dexamethasone (R-CVAD)

Indications

• chemotherapy regimen for treatment of lymphomas
  • Burkitt's lymphoma
  • lymphoblastic lymphoma
• acute lymphoblastic leukemia

Dosage

• six 21-day cycles
  • rituximab (375 mg/m2) administered on day 1 of each cycle
  • on days 1-5
    • cyclophosphamide (400 mg/m2)
    • doxorubicin (25 mg/m2)
    • vincristine (1 mg capped dose)
    • dexamethasone

More general terms

• antineoplastic combination (combination chemotherapy)

Additional terms

• rituximab/cyclophosphamide/doxorubicin/vincristine (Oncocin)/prednisone (R-CHOP)

Components

• rituximab (Rituxan, Mabthera, Truxima, Ruxience, Riabni)
• vincristine; 22-oxovincaleukoblastine; leurocristine (Oncovin, Vincasar PFS)
• doxorubicin (Adriamycin, Rubex)
• cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271]
• dexamethasone (Decadron, Maxidex, AK-Dex, Ozurdex)